All In Biotech

Drug Trial Radar · NCT03800017

Skeletal Muscle Function in Interstitial Lung Disease

Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 7, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
University of British ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.

Conditions

  • Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis
  • Hypersensitivity Pneumonitis
  • Scleroderma
  • Nonspecific Interstitial Pneumonia

Interventions

  • HyperoxiaBiological

    Participants breathe 60% oxygen during exercise

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in standardized dyspnea score during the constant load exercise test (visit 3)Time frame: Dyspnea will be measured once every minute during exercise on visit 3 (up to 7 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)
  2. Change in standardized dyspnea score during the constant load exercise test (visit 4)Time frame: Dyspnea will be measured once every minute during exercise on visit 4 (up to 8 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)
  3. Change in leg muscle strength measured following the constant load exercise test (visit 3)Time frame: Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 3 (up to 8 weeks after baseline)
  4. Change in leg muscle strength measured following the constant load exercise test (visit 4)Time frame: Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 4 (up to 8 weeks after baseline)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.